durvalumab,sorafenib,tremelimumab,cisplatin,gemcitabine,pembrolizumab
astrazeneca,pfizer,merck
['hcc']
fantastic analysis of qol studies in hcc/ biliary cancers by ! #asco23 
Gastrointestinal medical oncologist @clevelandclinic. Tweets are my own.